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Abstract
Background: In the present study we assessed the functional state of the major mediator of the immune
response, the complement system, in post-traumatic stress disorder (PTSD).
Methods: Thirty one PTSD patients within 13 years from traumatic event and the same number of sex- and age-
matched healthy volunteers were involved in this study. In the blood serum of the study subjects hemolytic
activities of the classical and alternative complement pathways, as well as the activities of the individual
complement components have been measured. Correlation analysis between all measured parameters was also
performed.
Results: According to the results obtained PTSD is characterized by hyperactivation of the complement classical
pathway, hypoactivation of the complement alternative pathway and overactivation of the terminal pathway.
Conclusions: The results obtained provide further evidence on the involvement of the inflammatory component
in pathogenesis of PTSD.
Background
Post-traumatic stress disorder (PTSD) is a complex,
severe and chronic psychiatric illness, an anxiety disor-
der (DSM-IV-TR code: 309.81; ICD-10 code: F43.1,
F62.0) that can develop in a person after exposure to a
terrifying event (or after witnessing or learning about
such an event) or ordeal in which grave physical harm
occurred or was threatened. Traumatic events that may
trigger PTSD include violent personal assaults, natural
or human-caused disasters, terrorist attacks, accidents,
or military combats. The person’s response to the event
must involve intense fear, helplessness, or horror. PTSD
is clinically manifested with three main syndromes: re-
experiencing; avoidance behavior and numbing of emo-
tion; and physiological hyperarousal, accompanied by a
number of “somatic” pathologies. Symptoms usually
begin within the first 3 months after the traumatic event
and last for many years, although there may be a delay
of months, or even years, before symptoms appear.
Patients with PTSD have a reduced quality of life, an
increased number of suicides and hospitalizations, high
frequency of depressions and alcohol drug abuse; social,
family life and work become impossible [1-5].
The molecular pathomechanisms of PTSD are not
well defined and only beginning to be understood,
which has limited the progress in development of the
efficient measures of PTSD-therapy. Promising findings
suggest that both environment and genetic factors are
involved in PTSD-generation mechanisms [6], and that
alterations in the immune reactivity might be in a suffi-
cient degree responsible for disease progression [7,8].
M o r e o v e r ,t h e r ei sag r o w i n gb o d yo fe v i d e n c eo nt h e
important role of inflammation in pathogenesis of PTSD
[9-17]. However, due to insufficiency of relevant data, a
molecular picture of the immune system abnormalities
in PTSD is yet unclear.
The complement system is major effector of the
immune response, which acts on the interface of innate
and adaptive immunity, and is a key component and
trigger of many immunoregulatory mechanisms. Activa-
tion of the complement through classical, alternative or
lectin pathways generates opsonins, anaphylatoxins, and
chemotaxins, mediators of inflammation and apoptosis
[18-20]. Alterations in the functional activity of the
complement cascade contribute to the pathology of
many human diseases [21-23], including mental
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gical stress [33,34]. The alterations in the complement
cascade have been considered as indicator of the impli-
cation of inflammatory component in disease etiology,
pathogenesis and/or progression [21-23]. Whereas
PTSD-affected subjects showed a low-grade systemic
proinflammatory state, which, moreover, was related to
PTSD symptom levels [9-17], the state of the comple-
ment system in PTSD have been never studied.
The aim of the present study was to assess the func-
tional activity of the complement cascade in PTSD by
determining total hemolytic activities of its classical
and alternative pathways, and hemolytic activities of its
individual components, C2, C3, C4, factor B and factor
D, in the blood serum of PTSD affected and healthy
subjects. C2 and C4 are main components of the classi-
cal pathway, factor B and factor D are essential compo-
nents of the alternative pathway, and C3 is the initial
point for the alternative pathway and a converge point
of all three complement activation pathways, starting
up for the terminal pathway [18-20]. In addition, corre-
lation study between all measured parameters was also
performed.
Methods
Study subjects
In the present study 31 PTSD affected subjects (males
27, females 4; mean age 42 ± 4.6 (mean ± S.E.)), combat
veterans within 13 years from traumatic event were
examined. All the affected subjects were hospitalized at
the Stress Center. Blood sampling was performed before
any medication was applied. Diagnosis of PTSD was
determined by the Structured Clinical Interview for
Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV (SCID-I) [35] and the Clinician Administered
PTSD Scale (CAPS) [36]. Age- and sex matched healthy
controls (n = 31) were volunteers from the Institute of
Molecular Biology without any history of physical or
sexual abuse or other major trauma, defined as being
free of current or past psychiatric disorders as deter-
mined by structured interview (SCID-I) and leading an
active and independent life. The exclusion criteria were
participant reports on a) immune, cardiovascular, cere-
brovascular, metabolic, oncological, or kidney disorders;
b) current cold, respiratory or other infections; c) pre-
scribed medication, use of any anti-inflammatory or
antihistamine medication or immunosupressors in the
last 12 months; c) any surgical invention in the last 12
months.
All subjects gave their informed consents to provide 5
ml of venous blood for the study, and the study was
approved by the Ethical Commi t t e eo ft h eI n s t i t u t eo f
Molecular Biology.
Collection of blood and preparation of serum
Practically fasting blood samples were collected by veni-
puncture in appropriate tubes at 9:00-10:00 a.m. and
kept on ice for 60 min. After that the blood was centri-
fuged at 3000 g for 15 min at 4°C to separate serum
from blood corpuscles. The obtained serum samples
were stored in aliquots at -30°C and thawed immediately
prior to use. To check inter-test repeatability of the
results, each study subject was sampled twice within the
interval of 2 days. Healthy subject were additionally
sampled after 6 months. That was impossible to perform
in case of PTSD-affected subjects, because after the sec-
ond sampling they have started to use medication and
even after discharge from the hospital continued to use
supporting therapy, which may interfere the results of
this study.
Hemolytic assays
Hemolytic activities of the complement classical and
alternative pathways (CH50 and AH50, respectively) and
of the complement components C2 (C2H50), C3
(C3H50), C4 (C4H50), factor B (fBH50), and factor D
(fDH50) in the blood serum of PTSD-affected and
h e a l t h ys u b j e c t sw e r em e a s u r e db ye a r l i e rd e v e l o p e d
assays [37]. Measuring AH50, fDH50, and fBH50, rabbit
erythrocytes were used as target cells. For CH50,
C2H50, C3H50 and C4H50 assays, sheep erythrocytes
sensitized with rabbit anti-sheep erythrocyte antibodies
were used as target cells. The hemolytic activity was
expressed in units/ml. One unit of hemolytic activity is
defined as an amount of serum that causes a 50% hemo-
lysis of erythrocytes in a reaction mixture. The hemoly-
tic titer is the number of units per ml of serum, and is
calculated as the reciprocal of the serum dilution, which
gives 50% cell lysis. Sheep erythrocytes sensitized with
rabbit anti-sheep erythrocyte antibodies (5 × 10
8 cells/
ml) and rabbit erythrocytes (1 × 10
8 cells/ml) were pre-
pared as previously described [38].
Preparation of depleted sera
Factor B-, factor D-, C2-, C3- and C4-depleted sera for
fBH50, fDH50, C2H50, C3H50 and C4H50 assays,
respectively, were prepared according to previously
developed methods [39]. Factor B- and C2-depleted sera
were obtained by incubating human fresh serum in 50°C
water bath for 20 min and 56°C water bath for 6 min,
respectively. Factor D was selectively depleted from
human serum by Sephadex G-75 gel filtration. C3
depleted serum was obtained by treatment of guinea pig
serum with zymosan, and complement C4 depleted
s e r u mw a so b t a i n e db yi n c u b a t i o no fg u i n e ap i gs e r u m
with 150 mM NH4OH for 45 min at 37°C. The effi-
ciency of depletion (≥ 95%) was judged by ELISA.
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Data were analysed by Student’s unpaired two-tailed
t-test and Pearson’s correlation analysis. A value of
p < 0.05 was considered significant.
Results
To assess the functional state of the complement in
PTSD, we measured CH50, AH50, C2H50, C3H50,
C4H50, fBH50, and fDH50 in the blood serum of PTSD
affected and healthy subjects. The results obtained not
depend on the period of blood sampling, thus demon-
strating good inter-test repeatability, and are presented
in table 1.
According to the results obtained, mean values of
serum CH50, C2H50 and C4H50 in PTSD patients were
2.1, 1.2 and 1.6 times significantly higher than in case of
healthy subjects. On the contrary, mean values of serum
C3H50, AH50, fBH50, and fDH50 in PTSD patients
were 1.5, 1.7, 1.6, and 2.3 times significantly lower as
compared to healthy subjects. The detected changes
positively and significantly correlated (p < 0.05) with
total (frequency and intensity) PTSD symptom cluster
of re-experiencing, avoidance, and hyperarousal, and
with PTSD total symptom score.
Correlation analysis also demonstrated that in PTSD
affected subjects C3H50 is significantly correlated with
C2H50 and C4H50 (r = 0.72; p = 0.002; r = 0.5; p =
0.05 respectively), and AH50 is significantly correlated
with C3H50 (r = 0.57; p = 0.027). However, we did not
observe other significant correlations among measured
parametrs in PTSD. The results of correlation analysis
are presented in table 2.
No significant correlation between the above-men-
tioned parametrs was detected in the healthy subjects
group (p > 0.05).
Discussion
The complement system with its central position in
innate and adaptive immunity mediates a variety of
effector functions. It consists of more than 30 circulat-
ing proteins and a similar number of cell surface
receptor and regulator proteins. It is a complex cascade
involving proteolytic cleavage of serum glycoproteins
often activated by cell receptors. This cascade ultimately
results in induction of the antibody responses, inflam-
mation, phagocyte chemotaxis, and opsonization of
apoptotic and necrotic cells, facilitating their recogni-
tion, clearance, and lysis. Complement exhibits three
activation pathways - classical, alternative, and lectin,
initiated via separate mechanisms, and a single terminal
pathway that results in a formation of the membrane
attack complex and subsequent cell lysis [18-20].
During the past decades it has become evident that
dysfunction of complement contributes to the pathology
of many human diseases [21-23], including mental dis-
orders (schizophrenia, Alzheimer’s disease, Huntington’s
and Pick’s diseases) [24-32], and is also detected during
physiological stress [33,34]. However, no data on the
state of the complement system in PTSD have been
reported, whereas a number of studies suggest that a
direct pathophysiological consequence of PTSD is
chronic low grade activation of systemic vascular inflam-
mation [15-17]. Compared to controls, patients with
PTSD showed higher WBC count [39], circulating levels
of C-reactive protein [13], interleukin (IL)-1b [14,9], IL-
6 and IL-6 receptor [10,11], as well as lower levels of
the anti-inflammatory cytokine IL-4 [12].
This study was focused on the functional state of the
major mediator of the inflammation, the complement
system, in PTSD. The results obtained clearly demon-
strated that pathogenesis of PTSD is characterized by
complement dysfunction including hyperactivation state
of the complement classical pathway and hypoactivation
state of the complement alternative pathway.
The alternative pathway of complement is activated
following spontaneous hydrolysis of the thioester bond
Table 1 Mean values of measured parameters in PTSD
patients and healthy subjects.
Parameter HS
(M ± S.E.)
PTSD
(M ± S.E.)
difference p =
CH50 176 ± 24.56 375 ± 29.52 2.1↑ 0.0002
C2H50 58.8 ± 3.1 67.6 ± 1.63 1.2↑ 0.05
C3H50 55.92 ± 1.82 37.57 ± 4.2 1.5↓ 0.002
C4H50 36.64 ± 7.68 60.1 ± 7.3 1.6↑ 0.03
AH50 87.6 ± 2.13 52.3 ± 3.37 1.7↓ 0.0001
fBH50 65.2 ± 12.9 40.8 ± 3.6 1.6↓ 0.02
fDH50 163.7 ± 24.95 71.7 ± 3.99 2.3↓ 0.001
Table 2 Analysis of correlation between measured
parameters in PTSD patients.
rp =
CH50 versus C2H50 0.108 0.7
CH50 versus C3H50 -0.24 0.39
CH50 versus C4H50 -0.42 0.12
C2H50 versus C3H50 0.72 0.002
C2H50 versus C4H50 0.12 0.66
C3H50 versus C4H50 0.5 0.05
AH50 versus fBH50 0.155 0.6
AH50 versus fDH50 0.21 0.44
fBH50 versus fDH50 0.17 0.52
AH50 versus C3H50 0.57 0.027
AH50 versus CH50 0.087 0.66
fDH50 versus C3H50 0.34 0.22
fBH50 versus C3H50 -0.44 0.1
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cleaved by factor D, generating the efficient alternative
pathway C3 convertase C3bBb. Multifunctional comple-
ment protein C3 is the initial point of the alternative
p a t h w a y ,a n d ,a tt h es a m et i m e ,ac o n v e r g ep o i n to fa l l
three complement activation pathways, i.e. starting point
for the terminal pathway [16-18].
Hypoactivation state of the alternative pathway
together with decreased activity of the complement C3
component, detected in PTSD affected subjects, prob-
ably reflects depletion of the C3 component due to its
overutilization through the terminal pathway. This
suggestion is convenient with correlation data indicat-
ing positive correlation between CH50 and C3H50
and absence of any correlation between AH50 and
fBH50, and AH50 and fDH50 in PTSD affected sub-
jects. Thus, it is obvious that the alternative pathway
in PTSD is supressed on the initial stage of its activa-
tion, and that PTSD is also characterised by overacti-
vated terminal complement pathway. On the other
hand, absence of correlation between AH50 and CH50
suggests that alterations in activities of the classical
and the alternative complement pathways in PTSD are
not interdependent. As it was mentioned above,
alterations in the complement cascade have been con-
sidered as indicator of the implication of inflammatory
component in disease etiology, pathogenesis and/or
progression [21-23].
Our study demonstrates that PTSD is associated with
dysfunction of the complement system, and reveals the
altered chains of the complement cascade. The results
obtained provide further evidence on the involvement of
the inflammatory component in pathogenesis of PTSD
demonstrated in a number of studies [9-17,39]. Here we
hypothesize that neuroendocrine mechanisms related to
PTSD [40,41] modulating the immune function [42,43]
might affect the initial steps in the inflammatory cascade
and thus influence alterations in the functional activity
of the major mediator of the inflammatory response, the
complement system. However, to address molecular
mechanisms responsible for the development of inflam-
matory processes and complement dysfunction in PTSD
as well as their role in PTSD pathogenesis further stu-
dies are needed.
Conclusions
1. Pathogenesis of PTSD is associated with the comple-
ment system dysfunction, including hyperactivation state
of the complement classical pathway, hypoactivation
state of the complement alternative pathway and overac-
tivation of the complement terminal pathway;
2. Alterations in the activities of the classical and the
alternative complement pathways in PTSD are not
interdependent;
3. The alternative pathway in PTSD is suppressed on
the initial stage of its activation.
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